Background: Considering the previous evidence regarding SARS/MERS outbreaks, ıt is expected that emergent psychiatric conditions such as mood disorders, anxiety, and depression disorders may occur in survivors of COVID-19. Objectives: In this study, the effects of clinical/neurological symptoms and sociodemographic characteristics of COVID-19 patients during the infection period on the level of anxiety/depression after recovery were investigated. Methods: Firstly, the socio-demographic characteristics of the participants and their clinical/ neurological symptoms during the infection period were determined. In addition, the Beck anxiety/depression scale was administered to the participants upon discharge. Then, the odds ratio of the variables was calculated by applying the Poisson regression method to determine the predictors affecting the level of anxiety/depression. Results: In this study, the clinical/neurological symptoms and the sociodemographic characteristics affecting the level of anxiety/depression were found to be associated with adults (mean age 45-years). The number of days of hospitalization was the only clinical feature that increased both anxiety and depression levels. In addition, post-discharge sleep disorder, headache, and alcohol use were found to be predictors of increased anxiety levels. In addition, smoking, the presence of a person with COVID-19 infection in the immediate vicinity, traveling in the last month before the illness, fever, and loss of smell during the infection period was found to increase the level of depression. Moreover, asthma was the only significant comorbidity that increased the anxiety level, while diabetes was the only comorbidity that increased the depression level. Conclusion: It is expected that this study will support social-psychological intervention and have some effects on reducing depressive/anxiety symptoms, which can vary widely in adults during stressful events.
Aim: This study aims to evaluate immature granulocyte count (IG#) and percentage (IG%) in the prediction of mortality in spontaneous intracerebral hemorrhage (SICH). Material and Method: Demographic characteristics and laboratory test results of patients diagnosed with SICH and admitted to the neurology clinic in a tertiary hospital between January 1, 2020, and January 1, 2022, were recorded. One hundred ten patients were included in the study. While 80 of these patients constituted the group that recovered after treatment, 30 of them formed the group that died despite treatment. IG and other laboratory and clinic parameters were statistically compared in both groups. Results: Of 110 patients, 45 (42.7%) were female, and 65 (57.3%) were male. IG counts were higher in the non-survival group than in the survival group (p=0.001). When the patients were divided according to low IG% (=0.6), 30 patients were in the high IG# group, and 80 patients were in the low IG% group. White blood cell (WBC), neutrophil count (NEUT#), monocyte count (MONO#), IG#, neutrophil-lymphocyte ratio (NLR), and hemorrhage volume (HV) values were statistically significantly higher in the high IG% group than in the low IG% group; Glasgow coma score (GCS) and percentage of lymphocytes (LYMPH%) values were significantly lower too. In addition, the mortality rate in the high IG# group was significantly higher than the mortality rate in the low IG% group (53.23% vs. 17.5%). Conclusion: IG is a new, easily accessible, inexpensive, and promising marker for predicting in-hospital mortality in patients with SICH.
Background We sought to examine the feasibility, safety and preliminary efficacy of anterior cerebral artery (ACA) occlusions in patients undergoing endovascular treatment. Methods Four hundred five consecutive patients with large-vessel occlusion treated with endovascular treatment were analysed to identify all patients with acute ACA occlusion who underwent endovascular treatment. Results Twenty had ACA occlusion (primary ACA occlusion: 9, rescue ACA occlusion: 11), 395 patients had other occlusions (internal carotid artery and MCA). The median [IQR] mRS score in the third month was significantly higher in the ACA-rescue occlusion group versus the ACA-primary occlusion group. The rate of haematoma in patients with ACA-occlusions was significantly higher compared with the ACA-primary occlusion group. Moreover, the three-month mortality rate was higher in patients with ACA-rescue than the patients with ACA-primary. Conclusions Although endovascular treatment can be considered in patients with primary ACA occlusions, our data suggest that future clinical trials are needed to determine the efficacy of endovascular treatment for ACA occlusions. Unfavourable outcomes in our study were considered to occur in the rescue ACA occlusions.
Introduction Endovascular treatment (ET) is a beneficial treatment for M1–2 occlusions of the middle cerebral artery. Mortality and disability rates are high if large vessel occlusions are not treated. While these rates are lower in M3 occlusions, important branch blockages can lead to disability. Endovascular treatment of small vessel occlusions is difficult, and there are no studies on the effectiveness of endovascular treatment for M3 occlusions. Accordingly, in this study, our aim was to assess the feasibility, safety, and preliminary efficacy of endovascular therapy for M3 occlusions. Methods This study involved a retrospective analysis of a prospectively collected from two centres for acute ischemic stroke of the anterior system between July 2015 and April 2020. Demographic, radiologic, procedural and outcome variables were collected for patients who underwent endovascular therapy for acute ischemic stroke of the anterior system. Results Complete or near complete reperfusion (mTICI 2b-3) of the M3 occlusion was achieved in 15 cases (38.5%). Complete (mTICI 3) reperfusion was achieved in 24 cases (61.5%). Twenty-six patients were treated for primary M3 occlusion, while 13 patients with M3 occlusion were treated as a rescue strategy after successful treatment of a proximal greater vascular occlusion. Complete or near complete reperfusion (mTICI 2b-3) of primary occlusion was achieved in eight cases (30.8%), and complete (mTICI 3) reperfusion was achieved in 18 cases (69.2%). In addition, complete or near complete reperfusion (mTICI 2b-3) of rescue M3 occlusion was achieved in seven cases (%53.8), while complete (mTICI 3) reperfusion was achieved in six cases (46.2%). Only one patient with primary M3 occlusion had ICH due to extravasation. The patient's neurological examination one month later was normal. Conclusions This retrospective study demonstrates that endovascular treatment of M3 occlusions is safe, effective and reliable.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.